Ninety-seven percent of patients received adjuvant radiation therapy (n = 272), 55.7% of patients received adjuvant hormone therapy (n = 156) (as a reminder 60% of patients were affected by a hormone receptor positive breast cancer) and 27.9% received neoadjuvant/adjuvant trastuzumab (n = 78) (28.9% had HER2 positive breast cancer). This evidence concerns the gene ERBB2 and breast carcinoma.